Clinical Trials Logo

Lupus clinical trials

View clinical trials related to Lupus.

Filter by:

NCT ID: NCT00710021 Completed - Clinical trials for Systemic Lupus Erythematosus

Vitamin D3 in Systemic Lupus Erythematosus

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.

NCT ID: NCT00657189 Completed - Clinical trials for Lupus Erythematosus, Systemic

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of multiple doses of MEDI-545 in subjects with moderately to severely active Lupus.

NCT ID: NCT00581763 Completed - Lupus Clinical Trials

Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies

APL
Start date: May 2001
Phase: N/A
Study type: Observational

This is a study about why some people have certain types of proteins in their blood, called anti-phospholipid antibodies. The presence of these antibodies and associated complications (e.g. blood clots) are known to change over time. The purpose of this study is to evaluate these changes and improve our ability to determine the long-term outcome of affected individuals.

NCT ID: NCT00482989 Completed - Lupus Clinical Trials

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

Start date: June 2007
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of multiple IV doses of the MEDIMUNNE antibody in adult patients with SLE.

NCT ID: NCT00339261 Completed - Lupus Clinical Trials

Disease Progression and Activity in Patients With Systemic Lupus Erythematosus

Start date: December 16, 2003
Phase: N/A
Study type: Observational

This study is a continuing follow-up of patients with systemic lupus erythematosus (SLE) and control subjects enrolled in the Carolina Lupus Study and the University of North Carolina (UNC) Lupus Nephritis Study. SLE is a severe, chronic, disabling autoimmune disease that significantly affects health and quality of life. The disease most often affects young to middle-aged adults, and therefore can also affect work and disability. There is currently little information on work-related disability related to SLE. The goals of the current study are to: - Determine health and work status of patients and controls in the Carolina Lupus Study and the UNC Lupus Nephritis Study; - Develop and test methods for obtaining disease data from university- and community-based physicians in the study area; - Examine the associations between sociodemographic, work-related factors, disease damage, and work disability among SLE patients and controls; and - Assess the role of demographic and socioeconomic factors, psychosocial attributes, and potentially modifiable behavior or environmental factors (e.g., smoking, occupational exposures, medication compliance) in disease damage measures, and in the increased severity of disease among African-American patients. Patients and control subjects enrolled in the Carolina Lupus Study and the University of North Carolina Lupus Nephritis Study are eligible for this protocol. Subjects will participate in a 30-minute telephone interview that includes questions related to their current health status, medical care utilization, work and disability issues, psychosocial attributes (e.g., helplessness, social support), and changes in environmental exposures since the previous follow-up interview in 2001. With the patients' permission, disease damaged will be assessed using a standardized form to be completed by the patients' physician or using information obtained from the patient's medical record.

NCT ID: NCT00299819 Completed - Lupus Clinical Trials

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

Start date: March 2006
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are receiving 20 mg/day or less of prednisone orally or an equivalent dose of another oral corticosteroid.

NCT ID: NCT00068874 Completed - Lupus Clinical Trials

Improving Quality of Life for African American Female Adolescents With Lupus

Start date: April 2004
Phase: Phase 2
Study type: Interventional

This study will evaluate a program designed to help African American adolescents with lupus (systemic lupus erythematosus or SLE) cope with the disease.

NCT ID: NCT00054938 Completed - Clinical trials for Systemic Lupus Erythematosus

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

Start date: March 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE). The study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, obesity, high blood pressure, and inactivity. The study will also test the safety of commonly used heart medications in people with lupus.

NCT ID: NCT00053560 Active, not recruiting - Lupus Clinical Trials

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).